Department of Rheumatology and Immunology, Hunan Provincial People's Hospital (The First-Affiliated Hospital of Hunan Normal University), No.89 Guhan Road, Furong District, Changsha, 410016, Hunan, People's Republic of China.
The First-Affiliated Hospital of Hunan Normal University (Hunan Provincial People's Hospital), Changsha, People's Republic of China.
Eur J Med Res. 2023 Nov 15;28(1):512. doi: 10.1186/s40001-023-01476-x.
The traditional treatment of rheumatoid arthritis (RA) has some side effects. We aimed to explore the effect of metformin treatment on the expression of HMGB1, cytokines, T cell subtypes and the clinical outcomes in RA patients.
The present prospective cohort study recruited 124 RA patients (metformin group) who were treated with metformin and conventional therapy (methotrexate, hydroxychloroquine sulfate and sulfasalazine) and 98 RA patients (conventional therapy group) who were only treated with conventional therapy. All subjects were admitted from December 2018 to December 2021 and continuous medication for 90 days. The serum high mobility group box 1 (HMGB1), tumor necrosis factor α (TNF-α), interleukin (IL)-6, IL-1β and C-reactive protein (CRP) levels were measured by enzyme-linked immunosorbent assay (ELISA). Flow cytometric were used to analyze the expression of CD4 and CD8. Demographic and clinical statistics including age, body mass index (BMI), sex, course of disease, erythrocyte sedimentation rate (ESR), rheumatoid factor (RF), visual analogue score (VAS)and disease activity score (DAS)-28 were collected.
The serum levels of HMGB1, CRP, IL-6, CD4+ expression and CD4+/CD8+ ratio were significantly increased in patients with DAS-28 score ≥ 2.6. The serum HMGB1 and cytokines levels of metformin group declined more quickly during the study time. Pearson's analysis supported that a positive correlation existed between the HMGB1 and IL-6, TNF-α, CRP, CD4, CD4/CD8 ratio, and VAS scores. HMGB1 could be a potential diagnostic biomarker for RA patients in active phase. Serum HMGB1 (95% CI 1.133-1.397, P < 0.001) was a factor associated with active RA.
The serum HMGB1 levels were significantly increased in RA patients in active phase. The serum levels of HMGB1 and inflammatory factors and VAS scores were decreased gradually with metformin treatment. HMGB1 might act as a novel therapeutic target for RA.
类风湿关节炎(RA)的传统治疗存在一些副作用。本研究旨在探讨二甲双胍治疗对 RA 患者高迁移率族蛋白 B1(HMGB1)、细胞因子、T 细胞亚群表达及临床结局的影响。
前瞻性队列研究纳入 2018 年 12 月至 2021 年 12 月期间 124 例接受二甲双胍联合常规治疗(甲氨蝶呤、硫酸羟氯喹和柳氮磺胺吡啶)的 RA 患者(二甲双胍组)和 98 例仅接受常规治疗的 RA 患者(常规治疗组)。所有患者均连续服药 90 d,采用酶联免疫吸附法(ELISA)检测血清高迁移率族蛋白 B1(HMGB1)、肿瘤坏死因子-α(TNF-α)、白细胞介素(IL)-6、IL-1β和 C 反应蛋白(CRP)水平,流式细胞术分析 CD4 和 CD8 的表达。收集人口统计学和临床统计资料,包括年龄、体重指数(BMI)、性别、病程、红细胞沉降率(ESR)、类风湿因子(RF)、视觉模拟评分(VAS)和疾病活动评分(DAS)-28。
DAS-28 评分≥2.6 的患者血清 HMGB1、CRP、IL-6、CD4+表达和 CD4+/CD8+比值明显升高。研究期间,二甲双胍组血清 HMGB1 和细胞因子水平下降更快。Pearson 分析支持 HMGB1 与 IL-6、TNF-α、CRP、CD4、CD4/CD8 比值和 VAS 评分呈正相关。HMGB1 可能是活动期 RA 患者的潜在诊断生物标志物。血清 HMGB1(95%CI 1.133-1.397,P<0.001)是与活动期 RA 相关的因素。
活动期 RA 患者血清 HMGB1 水平明显升高,二甲双胍治疗后血清 HMGB1 及炎症因子和 VAS 评分逐渐下降。HMGB1 可能成为 RA 的新型治疗靶点。